COVID-19 survivors in Seattle area can now donate plasma to potentially treat virus
Just a few weeks ago, Seattle-area plasma donation centers opened their doors to accept donations from those who have recovered from the novel coronavirus.
Grifols, a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, has officially begun identifying, screening and selecting volunteer donors who have recovered from the virus to donate their plasma at Grifols Biomat USA centers in the Seattle area, among other select U.S. cities like Chicago, Dallas, Houston, Los Angeles, San Antonio and San Diego.
The donated plasma will be used to produce a hyperimmune globulin that, if proven effective, could potentially treat the disease. This initiative is a result of a collaboration between Grifols, the U.S. Food and Drug Administration (FDA), the U.S. Biomedical Advanced Research Authority (BARDA), and other Federal health agencies.
Hyperimmune globulins are plasma-derived medicines effective in the treatment of severe acute infections like those of the novel coronavirus. Through the concentration of antibodies from plasma collected from recovered COVID-19 individuals, the hyperimmune globulin can offer precise and consistent dosing with high purity, high potency and a strong safety profile that may help current patients’ immune systems respond to the infection.
https://www.msn.com/en-us/news/us/covid-19-survivors-in-seattle-area-can-now-donate-plasma-to-potentially-treat-virus/ar-BB13DIKi?ocid=hplocalnews
